title: Postoperative irradiation of primary or recurrent pterygium: results and sequelae.
abstract: OBJECTIVE
  To evaluate the efficacy of postoperative beta irradiation and to analyze treatment sequelae in patients with primary and recurrent pterygium.
  
  
  METHODS
  From June 1986 to June 1998, 94 patients corresponding to 100 eyes received postoperative beta irradiation. Two groups of patients were treated: 37 eyes with primary pterygium (Group I) and 63 eyes with recurrent pterygium (Group II). Terson technique surgery was used in the majority of patients. Time between surgery and beta irradiation ranged from 2 to 48 h. Radiation doses and fractionation consisted of 30 Gy/3 fractions/5 days in 17 cases, 60 Gy/6 fractions/6 weeks in 80 cases, and 20 Gy/1 fraction in 3 patients.
  
  
  RESULTS
  Fourteen of the 100 cases (14%) treated with surgery and adjuvant irradiation recurred. The overall crude local recurrence rates were 5.4% for Group I and 19% for Group II patients. The 5-year probability of local tumor control was 83.5% for the whole group of patients, 94% for Group I, and 76.9% for Group II (p = 0.04). The early sequelae related to surgery or irradiation were self limited and disappeared by 6 months after the end of the treatment: ocular irritation (14 cases), scleral atrophy (5 cases), and neovascularization (7 cases). A greater incidence of sequelae was observed in Group II patients, but the difference between the groups was not statistically significant (p = 0.15). No significant correlation between treatment sequelae and treatment dose was noted: 29% sequelae with 30 Gy vs. 18.7% sequelae with 60 Gy (p = 0.32). No late complications have been observed.
  
  
  CONCLUSIONS
  Adjuvant beta irradiation provides effective therapy for primary pterygium, is somewhate less effective in patients with recurrent pterygium, and is associated with a moderate rate of early and transient sequelae.
authors.affiliation: Department of Radiation Oncology, University Hospital of Santa Maria, Lisbon, Portugal. mmonteir@mail.telepac.pt
authors.forename: I
authors.initials: I
authors.lastname: Monteiro-Grillo
authors.forename: L
authors.initials: L
authors.lastname: Gaspar
authors.forename: M
authors.initials: M
authors.lastname: Monteiro-Grillo
authors.forename: F
authors.initials: F
authors.lastname: Pires
authors.forename: J M
authors.initials: JM
authors.lastname: Ribeiro da Silva
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D011625:Pterygium / Q000532:radiotherapy* / Q000601:surgery*; D018714:Radiotherapy, Adjuvant; D012008:Recurrence; D013326:Strontium Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D013326:Strontium Radioisotopes